(CercleFinance.com) – Credit Suisse maintains its Outperformance opinion and its target price of $55 on the Pfizer share.
‘We believe the consensus significantly underestimates the potential of four key assets: Lyme disease vaccine, respiratory syncytial virus (RSV) vaccine, messenger RNA (mRNA) influenza vaccine and danuglipron ‘, explains the analyst.
These products could potentially be the first in their category, ‘in particular danuglipron, the first small molecule inhibitor of GLP-1’, notes Credit Suisse.
‘We are 19% above forecasts for 2030, forecasting an adjusted pipeline of 12.9 billion dollars, against 10.8 billion dollars in comparison’, adds the analyst before moderating his enthusiasm.
“Risks include: further deterioration in macroeconomic conditions, pricing headwinds, clinical trial pipeline risks and likely continued COVID-related sales declines. ‘
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.